Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Advance Bio Pharm IncfiledCriticalTaiwan Advance Bio Pharm Inc
Priority to SG200905843-9ApriorityCriticalpatent/SG169254A1/en
Publication of SG169254A1publicationCriticalpatent/SG169254A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re- population and number of circulating stem cells, particularly after chemotherapy or irradiation. Fig. 11
SG200905843-9A2009-09-032009-09-03Method of producing recombinant tat-hoxb4h protein for use as a stimulant of hematopoiesis in vivo
SG169254A1
(en)
Compounds derived from substituted pyrazolopyridine; pharmaceutical composition comprising them; method of preparation of the compounds, intermediates; and their use in the treatment of diseases, such as tumors, rheumatoid arthritis, diseases of deregulated vascular growth, among others.
PREPARATION OF HETEROLOGICAL POLYPEPTIDES IN MICROWATEREDES, EXTRA-CELLED MICROWAVE-ALONG CALVES, COMPOSITIONS AND METHODS OF THEIR RECEIVING AND APPLICATION
"method for decreasing expression, production or secretion of an angiogenic factor or hypertrophic factor or both by mesenchymal stem cells, methods for decreasing an inhibitory effect, a deleterious effect, and a mesenchymal stem cell apoptosis effect, a method for increasing a mesenchymal stem cell stimulating effect, composition, and method for preparing cartilage in an individual diagnosed with diseased or damaged cartilage. "
Pharmaceutical composition of evolocumab and its use, kit, method for preparing pcsk9-binding polypeptide and method for formulating therapeutic polypeptide